EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy

Katarzyna Budzynska iD, Katarzyna T Bozyk, Klaudia Jarosinska, Anna Ziemiecka, Krzysztof Siemionow, Maria Siemionow iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252010947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Katarzyna Budzynska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dystrogen Therapeutics Technology Polska sp. z o.o., 00-777 Warsaw, Poland. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Myoblasts, Dystrophin, Cell- and Tissue-Based Therapy. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dystrogen Therapeutics Technology Polska sp. z o.o., Dystrogen Therapeutics Technology Polska sp. z o.o.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne Muscular Dystrophy (DMD) is a lethal, X-linked disorder leading to muscle degeneration and premature death due to cardiopulmonary complications. Currently, there is no cure for DMD. We previously confirmed the efficacy of human Dystrophin-Expressing Chimeric (DEC) cells created via the fusion of myoblasts from normal and DMD-affected donors. The current study aimed to optimize the development of DEC therapy via the polyethylene glycol (PEG)-mediated fusion protocol of human myoblasts derived from normal, unrelated donors. The optimization of cell fusion assessed different factors influencing fusion efficacy, including myoblast passage number, the efficacy of PKH myoblast staining, the ratio of the single-stained myoblasts in the MIX, and PEG administration time. Additionally, the effect of PEG fusion procedure on cell viability was assessed. A correlation was found between the number of cells used for PKH staining and staining efficacy. Furthermore, the ratio of single-stained myoblasts in the MIX and PEG administration time correlated with fusion efficacy. There was no correlation found between the myoblast passage number and fusion efficacy. This study successfully optimized the myoblast fusion protocol for creation of human DEC cells, introducing DEC as a new Advanced Therapy Medicinal Product (ATMP) for DMD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMyoblastsDystrophinCell- and Tissue-Based TherapyCell FusionHumansPolyethylene GlycolsHybrid CellsCell SurvivalCells, Cultured

Stichwörter der Autor:innen

DEC therapyDuchenne muscular dystrophyadvanced therapy medicinal productcell fusiondystrophin-expressing chimeric (DEC) cells

Substanzen

DystrophinPolyethylene Glycols

Autor:innen und Institutionen

  • Dystrogen Therapeutics Technology Polska sp. z o.o., 00-777 Warsaw, Poland.
  • Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL 60607, USA.
  • Chair and Department of Traumatology, Orthopaedics, and Surgery of the Hand, Poznan University of Medical Sciences, 61-545 Poznan, Poland.

ORCID-Profile: Katarzyna Budzynska, Maria Siemionow

Förderung

  • Dystrogen Therapeutics Technology Polska sp. z o.o.
  • Dystrogen Therapeutics Technology Polska sp. z o.o

Zitieren

APA

Budzynska, K., Bozyk, K. T., Jarosinska, K., Ziemiecka, A., Siemionow, K., & Siemionow, M. (2024). Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252010947

Vancouver

Budzynska K, Bozyk KT, Jarosinska K, Ziemiecka A, Siemionow K, Siemionow M. Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252010947

BibTeX
@article{Budzynska2024,
  author = {Budzynska, Katarzyna and Bozyk, Katarzyna T and Jarosinska, Klaudia and Ziemiecka, Anna and Siemionow, Krzysztof and Siemionow, Maria},
  title = {Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252010947}
}
Kostenlos starten →